Healthcare

The milestone moves the company's lead Capture and Contain program into the final stretch before a planned clinical data readout.

The company said the change would prepare it for possibleEquityissuances tied to acquisitions and financing while keeping long-term control with a significantShareholderand long-time advisor. The board urged shareholders to vote in favor of all three proposals.

GAAPNet Incomerose 33% to US$1,949 million, or US$18.45 per diluted share, while non-GAAP net income increased 67% to US$2,150 million, or US$20.07 per diluted share. Chief Executive Officer Leonard S. Schleifer said Dupixent, EYLEA HD and Libtayo each achieved record net sales.

For Q3 2026, total revenue from continuing operations rose 26% to US$4.21 billion from US$3.33 billion a year earlier. Pharmacy Solutions revenue grew 26% to US$3.73 billion, while Provider Services revenue increased 31% to US$481 million.

On 21 October 2026, Genprex highlighted a peer-reviewed mouse study by researchers at Meharry Medical College, published in Mechanisms of Ageing and Development. Loss of TUSC2 disrupted mitochondrial function, protein homeostasis and neuronal communication pathways in the hippocampus, with markedly stronger effects in males. …

In September 2026, the FDA issued a not substantially equivalent determination on the initial 510(k) application for EchoSolv HF. On 12 October 2026, Echo IQ filed a request for supervisory review, which the FDA accepted, and the agency's Ombudsman was informed. A meeting with …

The year to 30 June 2026 closed with cash of just A$17,341 and net liabilities of A$33,439, before A$1.42 million in Brightside sale proceeds arrived in July.